Jubilant Pharmova recently released its Q1 financial results, showcasing a 9.2% increase in revenue to ₹1,901 crore compared to the same period last year. The company remains dedicated to its Vision 2030 strategy, focusing on investments in radiopharma, CRDMO, and sterile injectables to drive long-term growth. While net profit experienced a decline, earnings before interest, taxes, depreciation, and amortisation (EBITDA) saw a 14% growth to ₹302 crore.
The radiopharma segment showed promising growth, with revenue increasing by 3% year-on-year, supported by the success of PET imaging product Ruby-Fill. Additionally, the CDMO Sterile Injectables division experienced a 14% revenue increase, driven by strong customer interest in Line 3 at the Spokane facility. Clinical trials for proprietary drug candidates JBI-802 and JBI-778 are progressing as planned, showcasing the company’s commitment to innovation and growth.
Read more from cnbctv18.com